CEBP Susan G. Komen for the Cure-AACR Outstanding Investigator Award for Breast Cancer Research Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Murphy, S. E.
Right arrow Articles by Hatsukami, D. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Murphy, S. E.
Right arrow Articles by Hatsukami, D. K.
Cancer Epidemiology Biomarkers & Prevention Vol. 13, 1617-1623, October 2004
© 2004 American Association for Cancer Research

A Comparison of Urinary Biomarkers of Tobacco and Carcinogen Exposure in Smokers

Sharon E. Murphy, Carrie A. Link, Joni Jensen, Chap Le, Susan S. Puumala, Stephen S. Hecht, Steven G. Carmella, London Losey and Dorothy K. Hatsukami

Transdisciplinary Tobacco Use Research Center and Cancer Center, University of Minnesota, Minneapolis, Minnesota

Requests for reprints: Sharon E. Murphy, University of Minnesota Cancer Center, Mayo Mail Code 806, 420 Delaware Street Southeast, Minneapolis, MN 55455. Phone: 612-624-7633; Fax: 612-626-5135. E-mail: murph062{at}umn.edu

Recently, several potential harm reduction strategies, such as reduction in the number of cigarettes smoked and the use of modified cigarette products, have been discussed as possible means by which to reduce tobacco-related disease. To assess any potential reduction in harm by either of these approaches requires an accurate assessment of tobacco toxin exposure. We have recently completed a cigarette reduction study in which smokers were required to reduce the number of cigarettes smoked by 75%. This reduction took place over a 6-week period. We report here the comparison of urinary concentrations of tobacco alkaloid and tobacco carcinogen biomarkers in a subset of these same smokers during a 7-week period prior to any reduction in cigarette consumption. Urine samples were collected at four time points and analyzed for 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), and its glucuronide, 1-hydroxypyrene, anatabine, free nicotine, total nicotine (free plus glucuronidated), free cotinine, total cotinine (free plus glucuronidated), and total trans-3'-hydroxycotinine (free plus glucuronidated). Anatabine is a minor alkaloid that may be useful in assessing tobacco exposure in individuals using nicotine replacement therapies. Urinary anatabine levels were well correlated (P < 0.0001) with both free and total nicotine (r = 0.753 and 0.773, respectively). Anatabine levels were also correlated with free cotinine (r = 0.465; P < 0.001), total cotinine (r = 0.514; P < 0.001), and total NNAL (r = 0.633; P < 0.001). These data support the role of anatabine as a biomarker of tobacco exposure. 1-Hydroxypyrene is a biomarker of polycyclic aromatic hydrocarbon exposure, but unlike NNAL it is not tobacco specific. Whereas urinary concentrations of 1-hydroxypyrene were consistent across the four visits, the levels were not correlated with NNAL, anatabine, nicotine, or any nicotine metabolites.




This article has been cited by other articles:


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
M. E. Mooney, Z.-z. Li, S. E. Murphy, P. R. Pentel, C. Le, and D. K. Hatsukami
Stability of the Nicotine Metabolite Ratio in ad Libitum and Reducing Smokers
Cancer Epidemiol. Biomarkers Prev., June 1, 2008; 17(6): 1396 - 1400.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
I. Stepanov, S. S. Hecht, B. Lindgren, P. Jacob III, M. Wilson, and N. L. Benowitz
Relationship of Human Toenail Nicotine, Cotinine, and 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol to Levels of These Biomarkers in Plasma and Urine
Cancer Epidemiol. Biomarkers Prev., July 1, 2007; 16(7): 1382 - 1386.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
A. M. Joseph, S. S. Hecht, S. E. Murphy, S. G. Carmella, C. T. Le, Y. Zhang, S. Han, and D. K. Hatsukami
Relationships between Cigarette Consumption and Biomarkers of Tobacco Toxin Exposure
Cancer Epidemiol. Biomarkers Prev., December 1, 2005; 14(12): 2963 - 2968.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
N. D. Gross, J. O. Boyle, J. D. Morrow, M. K. Williams, C. S. Moskowitz, K. Subbaramaiah, A. J. Dannenberg, and A. J. Duffield-Lillico
Levels of Prostaglandin E Metabolite, the Major Urinary Metabolite of Prostaglandin E2, Are Increased in Smokers
Clin. Cancer Res., August 15, 2005; 11(16): 6087 - 6093.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
N. L. Benowitz, P. Jacob III, J. T. Bernert, M. Wilson, L. Wang, F. Allen, and D. Dempsey
Carcinogen Exposure during Short-term Switching from Regular to "Light" Cigarettes
Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1376 - 1383.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2004 by the American Association for Cancer Research.